Heart Disease Community
Atenolol for LQT?
About This Community:

This patient support community is for discussions relating to angina, angioplasty, arrhythmia, bypass surgery, cardiomyopathy, coronary artery disease, defibrillator, heart attack, heart disease, mitral valve, pacemaker, PAD, stenosis, and stress tests.

Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

Atenolol for LQT?

Dear Cleveland MD:

Atenolol seemed to cause higher mortality in LQT pediatric patients in older literature.

More recently, another article points out the inferiority of Atenolol:

Abstract
Beta-blocker therapy is one of the principal therapies for congenital long-QT syndrome (LQTS). However, breakthrough cardiac events occur while being treated with beta-blockers. We sought to determine the frequency of and clinical correlates underlying beta-blocker therapy failures in genotyped, symptomatic LQTS probands. The medical records were analyzed only for genotyped LQTS probands who presented with a LQTS-attributable clinical event and were receiving beta-blocker therapy. The study cohort comprised 28 such patients: 18 KCNQ1/KVLQT1(LQT1), 7 KCNH2/HERG (LQT2), and 3 SCN5A (LQT3). The prescribed beta-blocker was atenolol (12), propranolol (10), metoprolol (4), and nadolol (2). Beta-blocker therapy failure was defined as breakthrough cardiac events including syncope, aborted cardiac arrest (ACA), appropriate implantable cardioverter-defibrillator (ICD) therapy, or sudden death occurring while on beta-blocker therapy. During a median follow-up of 46 months, 7/28 (25%) LQTS probands experienced a total of 15 breakthrough cardiac events. Their initial presentation was ACA (3), bradycardia during infancy (2), and syncope (2). The underlying genotype was KVLQT1 (6) and HERG (1). Two breakthroughs were attributed to noncompliance. Of the 13 breakthroughs occurring while compliant, 10 occurred with atenolol and 3 with propranolol (p = 0.03). In this study cohort, one-fourth of genotyped LQTS probands failed beta-blocker therapy. Treatment with atenolol, young age at diagnosis, initial presentation with ACA, KVLQT1 genotype, and noncompliance may be important factors underlying beta-blocker therapy failures.

Why is Atenolol still being used?

Thanks


This discussion is related to Long QT Syndrome.
Related Discussions
Post a Comment
To
Top Heart Disease Answerers
976897_tn?1379171202
Blank
ed34
watford, United Kingdom
63984_tn?1385441539
Blank
Flycaster305
97303, OR
Avatar_f_tn
Blank
skydnsr
159619_tn?1318997813
Blank
erijon
Salt Lake City, UT
329165_tn?1412685860
Blank
Smiley2000
Australia
Avatar_m_tn
Blank
Occupant
IL
MedHelp Health Answers
Blank
BloodPressure Tracker
Monitor Your Blood Pressure
Start Tracking Now
Blank
HeartRhythm Tracker
Track your Heart Condition
Start Tracking Now
Recent Activity
1806721_tn?1388096157
Blank
Pregnancy journal (week 10)
8 hrs ago by Annie_777
1236893_tn?1408490528
Blank
gymdandee commented on Dietary Fat Increases...
Nov 27
Avatar_m_tn
Blank
Paxiled commented on Dietary Fat Increases...
Nov 27
Heart Disease Community Resources
RSS Expert Activity
469720_tn?1388149949
Blank
Abdominal Aortic Aneurysm-treatable... Blank
Oct 04 by Lee Kirksey, MDBlank
242532_tn?1269553979
Blank
The 3 Essentials to Ending Emotiona...
Sep 18 by Roger Gould, M.D.Blank
242532_tn?1269553979
Blank
Control Emotional Eating with this ...
Sep 04 by Roger Gould, M.D.Blank
Top Heart Disease Answerers
976897_tn?1379171202
Blank
ed34
watford, United Kingdom
63984_tn?1385441539
Blank
Flycaster305
97303, OR
Avatar_f_tn
Blank
skydnsr
159619_tn?1318997813
Blank
erijon
Salt Lake City, UT
329165_tn?1412685860
Blank
Smiley2000
Australia
Avatar_m_tn
Blank
Occupant
IL